AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
15 May 2014 03:28 PM
BZW
Form 8.3 - AstraZeneca Plc
15 May 2014 03:02 PM
BZW
Form 8.3 - AstraZeneca Plc
15 May 2014 01:52 PM
RNS
CONTINUING PROGRESS IN LATE STAGE PIPELINE
15 May 2014 12:56 PM
BZW
Form 8.3 - AstraZeneca PLC
15 May 2014 12:06 PM
BZW
Form 8.3 - Astrazeneca Plc - Amendment
15 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
15 May 2014 07:00 AM
RNS
AstraZeneca oncology pipeline update ahead of ASCO
14 May 2014 03:07 PM
BZW
Form 8.3 - AstraZeneca Plc
14 May 2014 03:00 PM
BZW
Form 8.3 - AstraZeneca Plc
14 May 2014 12:58 PM
BZW
Form 8.3 - AstraZeneca PLC
14 May 2014 11:01 AM
BZW
Form 8.3 - Astrazeneca Plc - Amendment
14 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
14 May 2014 07:00 AM
RNS
MedImmune announces immuno-oncology collaboration
13 May 2014 05:18 PM
BZW
Form 8.3 - Astrazeneca Plc - Amendment
13 May 2014 03:06 PM
BZW
Form 8.3 - AstraZeneca Plc
13 May 2014 02:43 PM
BZW
Form 8.3 - Astrazenica Plc
13 May 2014 12:59 PM
BZW
Form 8.3 - AstraZeneca PLC
13 May 2014 11:17 AM
BZW
Form 8.3 - Astrazeneca Plc - AMENDMENT
13 May 2014 11:15 AM
RNS
STATEMENT REGARDING PFIZER ANNOUNCEMENT
13 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
13 May 2014 10:57 AM
BZW
Form 8.3 - Astrazeneca Plc
13 May 2014 07:00 AM
RNS
AZ PHASE III SAXA/DAPA RESULTS
12 May 2014 06:16 PM
RNS
Form 8 (OPD) Pfizer Inc.
12 May 2014 06:15 PM
RNS
Form 8 (OPD) AstraZeneca PLC
12 May 2014 04:01 PM
RNS
AZ ANNOUNCES RESULTS OF PHASE IIB STUDIES
12 May 2014 04:00 PM
RNS
AZ TO PRESENT DATA AT ATS 2014
12 May 2014 03:25 PM
BZW
Form 8.3 - AstraZeneca Plc
12 May 2014 03:09 PM
BZW
Form 8.3 - Astrazenica Plc
12 May 2014 01:58 PM
BZW
Form 8.3 - AstraZeneca PLC
12 May 2014 12:12 PM
BZW
Form 8.3 - Astrazeneca Plc
12 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
12 May 2014 07:00 AM
RNS
AMGEN & AZ BRODALUMAB PHASE III RESULTS
09 May 2014 02:15 PM
BZW
Form 8.3 - Astrazeneca Plc
09 May 2014 02:06 PM
BZW
Form 8.3 - AstraZeneca Plc
09 May 2014 01:54 PM
BZW
Form 8.3 - AstraZeneca PLC
09 May 2014 11:43 AM
BZW
Form 8.3 - Astrazeneca Plc
09 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
08 May 2014 04:23 PM
BZW
Form 8.3 - AstraZeneca Plc
08 May 2014 02:08 PM
BZW
Form 8.3 - Astrazeneca Plc
08 May 2014 12:54 PM
BZW
Form 8.3 - AstraZeneca PLC
08 May 2014 12:31 PM
RNS
ASTRAZENECA INITIATES PHASE III STUDY FOR MEDI4736
08 May 2014 11:32 AM
BZW
Form 8.3 - Astrazeneca Plc
08 May 2014 11:02 AM
RNS
Rule 2.10 Announcement
07 May 2014 05:30 PM
RNS
Holding(s) in Company
07 May 2014 04:56 PM
BZW
Form 8.3 - Astrazeneca Plc
07 May 2014 03:27 PM
BZW
Form 8.3 - AstraZeneca Plc
07 May 2014 01:41 PM
BZW
Form 8.3 - AstraZeneca PLC
07 May 2014 01:39 PM
BZW
Form 8.3 - Astrazenica Plc
07 May 2014 11:18 AM
BZW
Form 8.3 - Astrazeneca Plc
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100